Evidence map›Paper›PMID 39964708›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2025

Tracking proteasome degradation: A cross-organ analysis via intact degradomics mass spectrometry.

Katharina I Zittlau, Daniel Zachor-Movshovitz, Yegor Leushkin, Roy Schimmel Brener, David Morgenstern, Gili Ben-Nissan, Michal Sharon

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Katharina I Zittlau *Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot 7610001, Israel.
Daniel Zachor-Movshovitz *Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot 7610001, Israel.ORCID 0009-0002-9671-2346
Yegor LeushkinDepartment of Biomolecular Sciences, Weizmann Institute of Science, Rehovot 7610001, Israel.
Roy Schimmel BrenerDepartment of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot 7610001, Israel.ORCID 0000-0001-5791-4872
David MorgensternNancy and Stephen Grand Israel National Center for Personalized Medicine, Weizmann Institute of Science, Rehovot 7610001, Israel.
Gili Ben-NissanDepartment of Biomolecular Sciences, Weizmann Institute of Science, Rehovot 7610001, Israel.
Michal SharonDepartment of Biomolecular Sciences, Weizmann Institute of Science, Rehovot 7610001, Israel.ORCID 0000-0003-3933-0595

Funding

EC | European Research Council (ERC) 101092725Israel Science Foundation (ISF) 946/23
6 · The paper itself

Abstract

The proteasome is a multisubunit degradation machinery that is essential for maintaining protein homeostasis by breaking down unnecessary or damaged proteins into peptides. While most of these peptides are further processed into amino acids, a subset evades complete degradation and plays key roles in biological processes such as antigen presentation, signaling, and apoptosis. However, the variability in peptide lengths and the diverse composition of proteasomes make their comprehensive identification and characterization particularly challenging. Here, we present a method that enables real-time identification of generated peptides, as well as uncleaved and partially cleaved protein substrates, revealing the processive nature of protein proteasomal degradation. Our intact degradomics workflow is based on intact mass spectrometry measurements and treats the enzymatically produced peptides as if they were generated within the mass spectrometer, akin to top-down products. We applied this approach to determine the kinetic profile of proteasome degradation and compare the real-time activity of proteasomes isolated from different mouse organs, uncovering distinct functionalities of the complex. Overall, this method offers a valuable tool for studying peptide degradation products across various proteasome configurations, while also enabling the investigation of how interacting proteins, inhibitors, and activators influence proteasome activity. Furthermore, its adaptability makes it applicable to a wide range of other proteolytic complexes, broadening its potential impact in the field.

Indexed as

Mass SpectrometryProteasome Endopeptidase ComplexProteolysisAnimalsMiceMice, Inbred C57BLPeptidesPeptidesProteasome Endopeptidase Complexmass spectrometryproteasomeprotein degradationtop-down MS

Identifiers

PMID39964708
PMCPMC11874349

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.